Shuttle Pharma reaches 25% enrollment in Phase 2 trial of Ropidoxuridine for glioblastoma

Shuttle Pharmaceuticals Holdings, Inc.

Initial randomization targets 40 patients: 20 at 1,200 mg/day, 20 at 960 mg/day to identify optimal dose.
After optimal dose selected, 14 more patients will be enrolled for survival comparison vs. historical controls.
Trial focuses on IDH wild-type, methylation-negative glioblastoma; standard care is radiation only.
Ropidoxuridine previously received FDA Orphan Drug Designation; six major cancer centers are participating.
CEO Anatoly Dritschilo said enrollment is ahead of expectations; no results or guidance changes reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.